NR1D1 and cardiac hypertrophy: REV-ERBα activation by SR9009 prevented the development of cardiac hypertrophy and reduced fibrosis. In NRVMs, SR9009 treatment enriched metabolic pathways downregulated in heart failure, particularly fatty acid metabolism.